[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.202.12. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
March 2009

Hypothalamic-Pituitary-Adrenal Axis Suppression in Systemic Glucocorticoid-Treated Infantile HemangiomasPutting the Risk Into Context

Arch Dermatol. 2009;145(3):319-320. doi:10.1001/archdermatol.2008.576

Hemangiomas of infancy (IH) are the most common benign tumor of childhood.1 When small and located in nonvital areas, IH may be safely observed; however, approximately 10% to 20% become “problematic” and require intervention (Figure).2 The gold standard therapy is systemic glucocorticoids (GCs).3 Glucocorticoids have the following well-recognized adverse effects in infants4: irritability, gastrointestinal tract upset, appetite change, decreased growth while receiving treatment, fungal skin infection, hirsutism, cushingoid facies, hypertension, pneumocystis pneumonia, and hypothalamic-pituitary-adrenal (HPA) axis suppression, a potentially devastating adverse effect, which in the appropriate clinical setting may lead to adrenal crisis.

First Page Preview View Large
First page PDF preview
First page PDF preview
×